Drugs currently authorised as of December 2024 for use in psoriatic arthritis. bDMARD, biological disease-modifying antirheumatic drug; csDMARD, conventional synthetic disease-modifying antirheumatic drug; DMARD, disease-modifying antirheumatic drug; IL, interleukin; JAK, Janus kinase; PDE4, phosphodiesterase
DMARD is a term that is used interchangeably with second-line medications, slow-acting antirheumatic drugs, or disease-controlling antirheumatic therapy. The
by E Choy 2024 Cited by 48rheumatoid arthritis; antirheumatic drugs, disease-modifying; antirheumatic agents; biological products; combined modality therapy; guidelines
antirheumatic drugs (csDMARDs). The most commonly used csDMARDs in antirheumatic drug, ILD interstitial lung disease, IVIg
An antirheumatic is any drug used in the treatment of rheumatism. Antirheumatics can reduce or prevent joint damage associated with inflammatory disorders of
by SS Zhao 2024 Cited by 17rheumatoid arthritis; antirheumatic drugs, disease-modifying; antirheumatic agents; biological products; rheumatology; treatment outcome
antirheumatic drugs (csDMARDs). The most commonly used csDMARDs in antirheumatic drug, ILD interstitial lung disease, IVIg
Disease-modifying antirheumatic drugs (DMARDs)/slow acting antirheumatic drugs (SAARDs)-. A. Nonbiological drugs-. 1. Immunosuppressants: Methotrexate
disease-modifying antirheumatic drugs (DMARD's). Tijdige behandeling met disease modifying antirheumatic drugs (DMARD's) voorkomt bij veel patiënten een
Comments